scholarly journals Role of Diameter Differences among Follicles in Selection of a Future Dominant Follicle in Mares1

1997 ◽  
Vol 57 (6) ◽  
pp. 1320-1327 ◽  
Author(s):  
E. L. Gastal ◽  
M. O. Gastal ◽  
D. R. Bergfelt ◽  
O. J. Ginther
Keyword(s):  
Dominant Follicle ◽  
Selection Of

Selection of the Dominant Follicle in Cattle: Role of Estradiol1

2000 ◽  
Vol 63 (2) ◽  
pp. 383-389 ◽  
Author(s):  
O.J. Ginther ◽  
D.R. Bergfelt ◽  
L.J. Kulick ◽  
K. Kot
Keyword(s):  
Dominant Follicle ◽  
Selection Of

scholarly journals Antimüllerian Hormone (AMH) Not Only a Marker for Prediction of Ovarian Reserve

2011 ◽  
pp. 217-223 ◽  
Author(s):  
R. HAMPL ◽  
M. ŠNAJDEROVÁ ◽  
T. MARDEŠIĆ
Keyword(s):  
Physiological Changes ◽  
Dominant Follicle ◽  
Female Development ◽  
Antimullerian Hormone ◽  
Pathological Conditions ◽  
Antimüllerian Hormone ◽  
Points Of View ◽  
Biomedical Fields ◽  
Selection Of

The main characteristics of the Antimüllerian hormone from the points of view of biochemistry, molecular genetics, physiological functions and importance for diagnostics in reproductive endocrinology and related biomedical fields are reviewed. The role of the hormone in male and female development, its participation in oocyte maturation including selection of a dominant follicle are summarized, as well as its changes under various pathological situations in both sexes. The physiological changes of serum AMH leves in the life span in both sexes and their alterations under various pathological conditions are provided, too.

Faculty selection of textbooks: Key variables and the role of teaching experience

2010 ◽  
Author(s):  
Aja Taitano ◽  
Bradley Smith ◽  
Cade Hulbert ◽  
Kristin Batten ◽  
Lalania Woodstrom ◽  
...  
Keyword(s):  
Teaching Experience ◽  
Key Variables ◽  
Faculty Selection ◽  
Selection Of

Posttransplant CMV infection and the role of immunosuppression (Sponsor: Novartis Pharma GmbH, Nürnberg)

2016 ◽  
Vol 04 (01) ◽  
pp. 4-10
Keyword(s):  
Lower Incidence ◽  
Paradigm Shift ◽  
Mtor Inhibitor ◽  
De Novo ◽  
Expert Panel ◽  
Risk Of Infection ◽  
Cmv Infection ◽  
Expert Meeting ◽  
Selection Of

AbstractImmunosuppression permits graft survival after transplantation and consequently a longer and better life. On the other hand, it increases the risk of infection, for instance with cytomegalovirus (CMV). However, the various available immunosuppressive therapies differ in this regard. One of the first clinical trials using de novo everolimus after kidney transplantation [1] already revealed a considerably lower incidence of CMV infection in the everolimus arms than in the mycophenolate mofetil (MMF) arm. This result was repeatedly confirmed in later studies [2–4]. Everolimus is now considered a substance with antiviral properties. This article is based on the expert meeting “Posttransplant CMV infection and the role of immunosuppression”. The expert panel called for a paradigm shift: In a CMV prevention strategy the targeted selection of the immunosuppressive therapy is also a key element. For patients with elevated risk of CMV, mTOR inhibitor-based immunosuppression is advantageous as it is associated with a significantly lower incidence of CMV events.

Sign in / Sign up

Export Citation Format

Share Document